| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
26,320,000 |
| Market
Cap: |
3.83(M) |
| Last
Volume: |
169,426 |
Avg
Vol: |
168,958 |
| 52
Week Range: |
$0.1454 - $0.1454 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Co. is developing multiple precision-targeted products based on its Manocept™ platform to improve patient care by identifying the sites and pathways of undetected disease and enable diagnostic, clinical decision-making and targeted treatment. Co.'s business is focused on two primary types of drug products: diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, including therapeutic applications of its Manocept platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Witter Malcolm G |
Director |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
13,000 |
|
- |
|
| Cutler Adam D. |
Director |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
10,000 |
|
- |
|
| Bruck Claudine |
Director |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
12,550 |
|
- |
|
| Rice Yehuda Michael |
Director |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
12,500 |
|
- |
|
| Rouan Sarah Kathryn |
Director |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
13,350 |
|
- |
|
| Witter Malcolm G |
Director |
– • – |
2020-12-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,500 |
|
- |
|
| Witter Malcolm G |
Director |
• • – |
2020-12-28 |
4 |
B |
$2.07 |
$10,350 |
D/D |
5,000 |
10,500 |
2.39 |
- |
|
| Kaufman Joel H. |
Chief Business OfficerOfficer |
• – – |
2020-11-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,368 |
|
- |
|
| Scott John K Jr. |
10% Owner |
– – • |
2020-08-30 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
8,047,162 |
2.37 |
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2020-08-14 |
4 |
A |
$0.00 |
$50 |
D/D |
50,000 |
107,997 |
|
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2020-06-02 |
4 |
A |
$2.62 |
$89,072 |
D/D |
33,997 |
57,997 |
|
- |
|
| Rosol Michael Stanley |
Chief Medical Officer |
• • – |
2020-06-02 |
4 |
A |
$2.62 |
$17,939 |
D/D |
6,847 |
13,097 |
|
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2020-02-20 |
4 |
B |
$1.08 |
$5,400 |
D/D |
5,000 |
17,950 |
2.81 |
- |
|
| Scott John K Jr. |
10% Owner |
– – • |
2020-02-13 |
4 |
B |
$0.85 |
$2,017,500 |
D/D |
2,373,529 |
8,042,162 |
2.45 |
- |
|
| Bruck Claudine |
Director |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
10,050 |
|
- |
|
| Rouan Sarah Kathryn |
Director |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
10,850 |
|
- |
|
| Rice Yehuda Michael |
Director |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
10,000 |
|
- |
|
| Cutler Adam D. |
Director |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$3 |
D/D |
2,500 |
7,500 |
|
- |
|
| Scott John K Jr. |
10% Owner |
– – • |
2019-12-06 |
4 |
B |
$0.90 |
$500,000 |
D/D |
555,555 |
5,668,633 |
2.45 |
- |
|
| Scott John K Jr. |
10% Owner |
– – • |
2019-06-18 |
4 |
B |
$0.75 |
$3,000,000 |
D/D |
4,000,000 |
5,113,078 |
2.45 |
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2019-06-05 |
4 |
B |
$1.26 |
$1,258 |
D/D |
1,000 |
12,950 |
2.73 |
- |
|
| Rouan Sarah Kathryn |
Director |
• • – |
2019-05-17 |
4 |
B |
$1.46 |
$4,904 |
D/D |
3,350 |
8,350 |
2.31 |
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2019-05-17 |
4 |
B |
$1.46 |
$1,463 |
D/D |
1,000 |
11,950 |
2.73 |
- |
|
| Latkin Jed |
CEO, COO & CFO |
• • – |
2019-05-16 |
4 |
B |
$1.45 |
$2,180 |
D/D |
1,500 |
10,950 |
2.73 |
- |
|
| Scott John K Jr. |
10% Owner |
– – • |
2019-03-22 |
4 |
B |
$0.14 |
$50,000 |
D/D |
357,143 |
22,261,565 |
2.45 |
- |
|
192 Records found
|
|
Page 4 of 8 |
|
|
